85 related articles for article (PubMed ID: 23114650)
1. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA
Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766
[TBL] [Abstract][Full Text] [Related]
2. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.
Herbert BS; Chanoux RA; Liu Y; Baenziger PH; Goswami CP; McClintick JN; Edenberg HJ; Pennington RE; Lipkin SM; Kopelovich L
Oncotarget; 2010 Oct; 1(6):405-422. PubMed ID: 21311097
[TBL] [Abstract][Full Text] [Related]
3. Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death.
Choe JH; Kawase T; Xu A; Guzman A; Obradovic AZ; Low-Calle AM; Alaghebandan B; Raghavan A; Long K; Hwang PM; Schiffman JD; Zhu Y; Zhao R; Lee DF; Katz C; Prives C
Cancer Discov; 2023 May; 13(5):1250-1273. PubMed ID: 37067901
[TBL] [Abstract][Full Text] [Related]
4. A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53.
Glazer RI
Oncotarget; 2010 Nov; 1(7):470-471. PubMed ID: 21317445
[No Abstract] [Full Text] [Related]
5. Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome.
Capaci V; Bascetta L; Fantuz M; Beznoussenko GV; Sommaggio R; Cancila V; Bisso A; Campaner E; Mironov AA; Wiśniewski JR; Ulloa Severino L; Scaini D; Bossi F; Lees J; Alon N; Brunga L; Malkin D; Piazza S; Collavin L; Rosato A; Bicciato S; Tripodo C; Mantovani F; Del Sal G
Nat Commun; 2020 Aug; 11(1):3945. PubMed ID: 32770028
[TBL] [Abstract][Full Text] [Related]
6. Rewired m
Xu A; Liu M; Huang MF; Zhang Y; Hu R; Gingold JA; Liu Y; Zhu D; Chien CS; Wang WC; Liao Z; Yuan F; Hsu CW; Tu J; Yu Y; Rosen T; Xiong F; Jia P; Yang YP; Bazer DA; Chen YW; Li W; Huff CD; Zhu JJ; Aguilo F; Chiou SH; Boles NC; Lai CC; Hung MC; Zhao Z; Van Nostrand EL; Zhao R; Lee DF
Nat Commun; 2023 Mar; 14(1):1694. PubMed ID: 36973285
[TBL] [Abstract][Full Text] [Related]
7. p53 and the pathogenesis of skin cancer.
Benjamin CL; Ananthaswamy HN
Toxicol Appl Pharmacol; 2007 Nov; 224(3):241-8. PubMed ID: 17270229
[TBL] [Abstract][Full Text] [Related]
8. Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program.
Gencel-Augusto J; Su X; Qi Y; Whitley EM; Pant V; Xiong S; Shah V; Lin J; Perez E; Fiorotto ML; Mahmud I; Jain AK; Lorenzi PL; Navin NE; Richie ER; Lozano G
Cancer Discov; 2023 May; 13(5):1230-1249. PubMed ID: 37067911
[TBL] [Abstract][Full Text] [Related]
9. p53 Oligomerization Domain Mutants: A New Class of Mutants That Retain "License to Kill".
Stieg D; Casey K; Murphy ME
Cancer Discov; 2023 May; 13(5):1046-1048. PubMed ID: 37139723
[TBL] [Abstract][Full Text] [Related]
10. Li-Fraumeni Syndrome in the Cancer Genomics Era.
Foulkes WD; Polak P
J Natl Cancer Inst; 2021 Nov; 113(12):1615-1617. PubMed ID: 34240211
[No Abstract] [Full Text] [Related]
11. Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.
Pantziarka P; Blagden S
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406393
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
13. Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche.
Pantziarka P
Ecancermedicalscience; 2015; 9():541. PubMed ID: 26082798
[TBL] [Abstract][Full Text] [Related]
14. Caspase Activation and Aberrant Cell Growth in a p53(+/+) Cell Line from a Li-Fraumeni Syndrome Family.
Sherif ZA
Genet Res Int; 2015; 2015():789201. PubMed ID: 25866679
[TBL] [Abstract][Full Text] [Related]
15. Caveolae and signalling in cancer.
Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Nat Rev Cancer; 2015 Apr; 15(4):225-37. PubMed ID: 25801618
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer nodal metastasis correlates with tumour and lymph node methylation profiles of Caveolin-1 and CXCR4.
Alevizos L; Kataki A; Derventzi A; Gomatos I; Loutraris C; Gloustianou G; Manouras A; Konstadoulakis MM; Zografos G
Clin Exp Metastasis; 2014 Jun; 31(5):511-20. PubMed ID: 24590865
[TBL] [Abstract][Full Text] [Related]
17. Li Fraumeni syndrome, cancer and senescence: a new hypothesis.
Pantziarka P
Cancer Cell Int; 2013 Apr; 13(1):35. PubMed ID: 23587008
[TBL] [Abstract][Full Text] [Related]
18. Rapalogs in cancer prevention: anti-aging or anticancer?
Blagosklonny MV
Cancer Biol Ther; 2012 Dec; 13(14):1349-54. PubMed ID: 23151465
[TBL] [Abstract][Full Text] [Related]
19. Divergent control of Cav-1 expression in non-cancerous Li-Fraumeni syndrome and human cancer cell lines.
Sherif ZA; Sultan AS
Cancer Biol Ther; 2013 Jan; 14(1):29-38. PubMed ID: 23114650
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
